-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: The course of subclinical rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is heterogeneous; some patients may experience disease progression leading to pulmonary symptoms and decreased respiratory functi.
OBJECTIVE: The course of subclinical rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is heterogeneous; some patients may experience disease progression leading to pulmonary symptoms and decreased respiratory functi.
Methods: One discovery sample and one validation sample were obtained from patients without pulmonary symptoms in 2 prospective RA cohorts ( ESPOIR and TRANSLATE2 ) who underwent chest HRCT scan.
RESULTS: The discovery and replication populations included 163 and 89 patients , respective.
Conclusions: This study identifies and validates a risk score for RA-ILD with or without MUC5B rs35705950 MUC5B rs35705950 that identifies patients at high risk for subclinical RA-ILD requiring screening with chest HRCT scan.
Source: Juge,.
Juge,.
.
, Granger,.
, et .
(2022), A Risk Score to Detect Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disea.
Arthritis Rheumat.
Accepted Author Manuscri.
https://d.
org/11002 /a.
42162 Leave a message here
